nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulfisoxazole—EDNRA—GPCRs, Other—DRD3—attention deficit hyperactivity disorder	0.0426	0.0426	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Other—DRD4—attention deficit hyperactivity disorder	0.0413	0.0413	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.0346	0.0346	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.0339	0.0339	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.0337	0.0337	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.0297	0.0297	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.0291	0.0291	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Other—HTR2A—attention deficit hyperactivity disorder	0.027	0.027	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.0235	0.0235	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.0226	0.0226	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.0221	0.0221	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.0206	0.0206	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.0201	0.0201	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.0191	0.0191	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.019	0.019	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.0185	0.0185	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.0182	0.0182	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.018	0.018	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.0176	0.0176	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.0173	0.0173	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.0167	0.0167	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.0164	0.0164	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.0159	0.0159	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.0156	0.0156	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.0154	0.0154	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.0153	0.0153	CbGpPWpGaD
Sulfisoxazole—EDNRA—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.0152	0.0152	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.0143	0.0143	CbGpPWpGaD
Sulfisoxazole—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.0136	0.0136	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.0134	0.0134	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.0128	0.0128	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.0125	0.0125	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.0125	0.0125	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.0121	0.0121	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.0119	0.0119	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.0117	0.0117	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.0117	0.0117	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.0116	0.0116	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.0114	0.0114	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.0109	0.0109	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.0102	0.0102	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.01	0.01	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00867	0.00867	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00805	0.00805	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00797	0.00797	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00787	0.00787	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00765	0.00765	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00758	0.00758	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00704	0.00704	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00688	0.00688	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00685	0.00685	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00682	0.00682	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00671	0.00671	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00671	0.00671	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00662	0.00662	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00658	0.00658	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.0064	0.0064	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.0062	0.0062	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00617	0.00617	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00609	0.00609	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00601	0.00601	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.0056	0.0056	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00465	0.00465	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.00432	0.00432	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00431	0.00431	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00428	0.00428	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00425	0.00425	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00406	0.00406	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.00392	0.00392	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00378	0.00378	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.00366	0.00366	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.0036	0.0036	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.00355	0.00355	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00331	0.00331	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.00232	0.00232	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00176	0.00176	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.00123	0.00123	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00122	0.00122	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00122	0.00122	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—DPYD—attention deficit hyperactivity disorder	0.0012	0.0012	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00111	0.00111	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000972	0.000972	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000926	0.000926	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—COMT—attention deficit hyperactivity disorder	0.000737	0.000737	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000732	0.000732	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.00071	0.00071	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—EP300—attention deficit hyperactivity disorder	0.000316	0.000316	CbGpPWpGaD
